Akebia Therapeutics, US Renal Care enter deal to offer Vafseo to patients on dialysis
Click Here to Manage Email Alerts
Key takeaways:
- The announcement comes after Akebia received FDA approval in March 2024.
- The contract will include all U.S. Renal Care dialysis centers.
Akebia Therapeutics and U.S. Renal Care have entered a multiyear commercial supply contract to offer the anemia drug Vafseo to patients on dialysis, according to a press release.
“We are excited to deliver a new choice in anemia management for dialysis patients and are extremely pleased to have entered into this supply agreement with U.S. Renal Care,” John P. Butler, CEO of Akebia, said in the release. “We see [U.S. Renal Care] USRC at the forefront of innovative care for patients on dialysis and we are pleased that they recognize Vafseo [vadadustat, Akebia Therapeutics]as an important option to make available for their patients. We believe that commitment to innovation will allow nearly 2,000 nephrologists access to prescribe Vafseo for patients living with kidney disease, as clinically appropriate.”
The agreement will include all U.S. Renal Care dialysis centers and allow attending physicians to prescribe vadadustat as deemed clinically appropriate. Akebia received FDA approval for the drug to treat chronic kidney disease-based anemia in adults who have been on dialysis for at least 3 months.
“U.S. Renal Care is pleased to partner with Akebia to make Vafseo accessible to our patients,” Mark Caputo, CEO of U.S. Renal Care, said in the release. “Our office [is] ... actively working on a protocol for Vafseo, and we believe nephrologists are eager to gain experience with an oral treatment that has the potential to advance the treatment of anemia due to CKD in dialysis patients.”
The drug is expected to become available and receive Transitional Drug Add-On Payment Adjustment designation in January 2025, according to the release.
Reference:
Akebia Therapeutics and U.S. Renal Care sign commercial supply contract to enable access to Vafseo (vadadustat) for patients on dialysis. https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-and-us-renal-care-sign-commercial-supply. Published Oct. 7, 2024. Accessed Oct. 7, 2024.
Read more about
Click Here to Manage Email Alerts